A phase 1 open-label study of the safety and feasibility of ZYC300 administration with cyclophosphamide pre-dosing.

Trial Profile

A phase 1 open-label study of the safety and feasibility of ZYC300 administration with cyclophosphamide pre-dosing.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2013

At a glance

  • Drugs ZYC 300 (Primary) ; Cyclophosphamide
  • Indications Breast cancer; Colon cancer; Ovarian cancer; Prostate cancer; Renal cancer; Various toxicities
  • Focus Adverse reactions
  • Most Recent Events

    • 12 May 2009 Actual patient number (22) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Oct 2008 Study sponsor changed from MGI Pharma to Eisai Medical Research, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top